Objective: We sought to quantitatively and objectively evaluate histomorphologic tumor regression and establish a relevant prognostic regression classification system for esophageal cancer patients receiving neoadjuvant radiochemotherapy. Patients and Methods: Eighty-five consecutive patients with localized esophageal cancers (cT2-4, Nx, M0) received standardized neoadjuvant radiochemotherapy (cisplatin, 5-fluorouracil, 36 Gy). Seventy-four (87%) patients were resected by transthoracic en bloc esophagectomy and 2-field lymphadenectomy. The entire tumor beds of the resected specimens were evaluated histomorphologically, and regression was categorized into grades I to IV based on the percentage of vital residual tumor cells (VRTCs). A major response was achieved when specimens contained either less than 10% VRTCs (grade III) or a pathologic complete remission (grade IV). Results: Complete resections (R0) were performed in 66 of 74 (89%) patients with 3-year survival rates of 54% Ϯ 7.05% for R0-resected cases and 0% for patients with incomplete resections or tumor progression during neoadjuvant therapy (P Ͻ 0.01). Minor histopathologic response was present in 44 (59.5%) and major histopathologic response in 30 (40.5%) tumors. Significantly different 3-year survival rates (38.8% Ϯ 8.1% for minor versus 70.7 Ϯ 10.1% for major response) were observed. Univariate survival analysis identified histomorphologic tumor regression (P Ͻ 0.004) and lymph node category (P Ͻ 0.01) as significant prognostic factors. Pathologic T category (P Ͻ 0.08), histologic type (P ϭ 0.15), or grading (P ϭ 0.33) had no significant impact on survival. Cox regression analysis identified dichotomized regression grades (minor and major histomorphologic regression, P Ͻ 0.028) and lymph node status (ypN0 and ypN1, P Ͻ 0.036) as significant independent prognostic parameters. A 2-parameter regression classification system that includes histomorphologic regression (major versus minor) and nodal status (ypN0 versus ypN1) was established (P Ͻ 0.001). Conclusions: Histomorphologic tumor regression and lymph node status (ypN) were significant prognostic parameters for patients with complete resections (R0) following neoadjuvant radiochemotherapy for esophageal cancer. A regression classification based on 2 parameters could lead to improved objective evaluation of the effectiveness of treatment protocols, accuracy of staging and restaging modalities, and molecular response prediction. (Ann Surg 2005;242: 684 -692) E sophageal cancer ranks among the 10 most frequent malignancies worldwide. Once diagnosed, the 5-year survival rate for these patients is about 10%.
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(Ann Surg 2005;242: 684 -692) E sophageal cancer ranks among the 10 most frequent malignancies worldwide. Once diagnosed, the 5-year survival rate for these patients is about 10%. 1 Surgery is the treatment of choice for most localized esophageal cancers. However, despite complete tumor resection and extensive lymphadenectomy, systemic and local recurrences are common and the 5-year survival rate ranges from 15% to 39%. 2 Surgical results have improved in recent decades; however, most of this can be attributed to advances in preoperative staging, patient selection, refinement of surgical techniques, and postoperative care. 3, 4 The particularly poor prognosis associated with locally advanced esophageal cancer prompted an evaluation of combined modality treatments using neoadjuvant chemotherapy, radiotherapy, or radiochemotherapy in combination with surgery. 5 The purported advantage of preoperative administration of chemotherapy, radiotherapy, or combined chemoradiation is that it may downstage the primary tumor, increase the resectability rate, eliminate micrometastases, and prolong survival.
Results of larger randomized phase III trials using preoperative chemotherapy [7] [8] [9] or radiochemotherapy 10 -12 were inconclusive; only 2 studies demonstrated a survival advantage for neoadjuvant treatment. 9, 10 Two recent meta-analyses of randomized trials showed modest but significant survival advantages for patients that received neoadjuvant chemotherapy 13 or radiochemotherapy. 14 In these trials, patients with a pathologic complete response have been consistently found to have impressive survival rates around 60%. 2 According to the World Health Organization (WHO), clinical response is graded as complete, partial (Ͼ50% tumor regression), minor/no change (Յ50% tumor regression), or progressive disease. 15 Clinical response evaluations using endoscopic ultrasound and computed tomography (CT), however, have been shown to be highly inaccurate. 16 In an effort to objectively evaluate response to neoadjuvant therapy, morphologic criteria have been defined for several cancers, including lung, 17 stomach, 18 and esophagus. 19, 20 Classification of regression based on the estimated percentage of vital residual tumor cells (VRTCs) was reported in non-small cell lung cancer patients following neoadjuvant radiochemotherapy. 17 In a prospective trial, the presence of Ͻ10% VRTCs was shown to be of significant prognostic importance by multivariate analysis. 21 We evaluated a modified regression classification system based on Junker et al, 17 also taking into account clinical response evaluation according to WHO. 15 Within a prospective observation trial consisting of patients receiving neoadjuvant radiochemotherapy for localized (cT2-4, Nx, M0) esophageal cancer, the potential for objective response classification was analyzed with regard to conventional "downstaging" as well as to prognostic implications concerning established clinical parameters.
PATIENTS AND METHODS

Study Population, Demographic Data, and Staging Procedures
All patients were recruited from a prospective observation trial starting in July, 1996 until December, 2003. During this period, 306 patients with esophageal cancer were scheduled for surgical resection in our institution. The study population consists of 85 patients (69 men, 16 women; median age, 59.2 years; range, 21.5-74.8 years) with localized esophageal cancers (cT2-4, Nx, M0). They represent all patients who received neoadjuvant radiochemotherapy according to a standardized protocol prior to surgical resection. Three experienced surgeons participated in all surgical procedures.
Eligibility criteria were histologically confirmed squamous cell carcinomas or adenocarcinomas of the esophagus. No prior treatment was allowed.
Locally advanced tumors (cT3-4) were included in the study group unless documented systemic metastases or bronchoscopically proven invasion of the tracheobronchial tree was present. Patients with cT2 tumors were offered this treatment when CT showed a tumor mass compatible with a T3 category; however, endoscopic ultrasound showed complete invasion of the muscularis propria but failed to demonstrate clear invasion of the adventitia (so-called "near T-3 categories"). Regionally enlarged lymph nodes including celiac nodes were allowed since they were completely resected by systematic radical 2-field lymphadenectomy as described. 22 Patients were required to have a Karnofsky Index Ͼ70% and normal to moderate risk factors for esophageal surgery according to a standardized score. 23 The age limit was set at 75 years or younger, and creatinine clearance had to be at least 60 mL/min. Patients with liver cirrhosis were also excluded from this study. No previous malignancies were allowed, with the exception of surgically cured basal cell cancer of the skin or carcinoma in situ of the cervix.
Written informed consent was obtained from each patient in accordance with the requirements of our institution's board of ethics.
TNM staging was performed according to the criteria of the International Union Against Cancer. 24 Clinical staging was based on a barium swallow, endoscopic ultrasound and CT of chest and abdomen (4-mm sections) and a technetium bone scan. Endoscopic ultrasound was performed in all patients by a single experienced examiner (H.S.). Diagnostic laparoscopy was performed in all patients diagnosed with adenocarcinomas to exclude peritoneal carcinomatosis. Relevant patient characteristics are summarized in Table 1 .
Radiochemotherapy Regimen and Surgical Resection
Cisplatin (20 mg/m 2 per day) was administered as a short-term infusion on days 1 to 5 and 5-fluorouracil (1000 mg/m 2 per day) as a continuous infusion over 24 hours on days 1 to 5. Radiation therapy was administered by linear accelerators with 10-to 15-MV photons. Radiation therapy was simulated to encompass the tumor volume with 5 cm cephalocaudal margins and 2-cm radial margins, and treatment ports were designed to include enlarged regional 11 Surgical resection was performed 4 to 5 weeks following completion of chemoradiation after clinical restaging using the same procedures as for staging, except for laparoscopy. Standardized transthoracic en bloc esophagectomy with radical 2-field lymphadenectomy as previously described 22 and reconstruction by gastric tube (n ϭ 72; 94.7%) or colon (n ϭ 4; 5.3%) interposition with either left cervical (n ϭ 28; 38.8%) or high intrathoracic anastomosis (n ϭ 48; 63.2%) was performed in patients who proceeded to surgical resection (n ϭ 74; 100%).
Pathology Examination and Histomorphologic Grading of Tumor Regression
The pathologic examination of the resected surgical specimens followed a standardized protocol in close cooperation of the operating surgeon and an experienced pathologist. Briefly, the macroscopically visible tumor or the suspected area was localized, measured, and completely embedded. All specimens were fixed in neutral-buffered formaldehyde and embedded in paraffin. Apart from the resection margins (oral, aboral, deep margins), macroscopically normal mucosa close and distant to the tumor was examined. Lymph nodes were extensively scrutinized as previously described. 22 Abdominal lymph node stations were classified according to the Japanese Gastric Cancer Association, 25 and mediastinal lymph nodes were separated into 3 groups: lower mediastinal, bifurcational (carinal, left and right mainstem bronchus), and upper mediastinal nodes. Histopathologic findings were classified according to the UICC TNM classification system. 24 Serial 5-m sections were stained with hematoxylin and eosin for evaluation of radiochemotherapy-induced regression. In case of diagnostic uncertainties, further staining procedures such as PAS, Elastica-van Gieson, or immunohistochemical analysis for cytokine expression were performed to identify individual cells. Therapy-induced changes included reactive changes such as necrosis, fibrosis, foamy histiocytes, and giant cell reactions. 17, 19, 20, 26 Meticulous attention was focused on these changes, especially with respect to the anatomic layers of the esophageal wall to characterize true downstaging and identify potential critical regions of radiochemotherapy. To account for the clinical response evaluation system according to WHO, 15 a classification system based on the estimated percentage of VRTCs was used. The degree of histomorphologic regression was classified into 4 categories: grade I, Ͼ50% VRTCs; grade II, 10% to 50% VRTCs (partial response); grade III, nearly complete response (NCR) with Ͻ10% VRTCs; and grade IV, complete response (pCR, ypT0). This analysis was performed by 2 staff pathologists who were blinded for all other clinical data (S.E.B. and J.T.). Regression grades III and IV were considered as major histomorphologic response (MiHR) compared with grades I and II constituting minor histopathologic response (MaHR).
Statistical Analysis
Associations between clinicopathologic parameters were evaluated using 2 analysis applying Fisher exact test for significance. Kaplan-Meier plots were used to describe the survival distribution with regard to important clinical parameters. 27 The log-rank test was used to evaluate survival differences. 28 Cox regression analysis was the method applied when several factors were assessed simultaneously. 29 The level of significance was set to P Ͻ 0.05. Unless otherwise specified, P values were given for 2-sided testing.
All statistical tests were performed using the Software Package SPSS for Windows, Version 11.0. (Chicago, IL).
RESULTS
Neoadjuvant Treatment: Toxicity, Dose Modification, and Tumor Progression
All 85 patients completed the radiotherapy regimen as planned. Dose modification within the chemotherapy regimen was necessary in 10 of 85 (11.7%) patients. This included reducing the tolerated doses of cisplatin and 5-FU to 80% (n ϭ 2), 60% (n ϭ 1), and 40% (n ϭ 1) and 5-FU only to 80% (n ϭ 4), 65% (n ϭ 1), and 20% (n ϭ 1). Toxicity was mild to moderate (WHO grade 1/2) and related to nausea, vomiting, mucositis, stenocardia, and allergic reactions. One patient experienced a grade 3/4 WHO hematologic toxicity (granulocytopenia, neutropenic fever). Another patient experienced a massive pulmonary embolism requiring a Trendelenburg operation. None of the patients required red blood cell transfusions prior to surgery.
A total of 11 patients (12.9%) developed local and/or systemic tumor progression (nonregional lymph nodes, n ϭ 3; tracheal infiltration, n ϭ 1; systemic metastases, n ϭ 8) and have therefore to be considered primary treatment failures. Clinical restaging performed 2 to 3 weeks following completion of neoadjuvant radiochemotherapy identified tumor progression in 9 of 11 patients. In 2 patients, systemic tumor progression (peritoneal carcinomatosis, 1; multiple small liver metastases, 1) was detected during laparotomy and so the operation did not proceed to resection.
Treatment was individualized for these patients: 6 patients received further radiochemotherapy, 4 patients had chemotherapy only, and 1 patient received best supportive care.
Patients with incomplete resections (R1 resections, n ϭ 8) received additional postoperative radiation therapy; 1 patient received up to a total field dose of 57.6 Gy and 7 patients received up to 63 Gy.
Surgical Results
Of the 85 patients that completed neoadjuvant radiochemotherapy, 74 (87.1%) were resected by transthoracic en bloc esophagectomy and radical 2-field lymphadenectomy.
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Sixty-six (89.2%) of the 74 resected patients received a complete resection (R0, resection according to UICC). In 8 patients, the resection was classified as incomplete by histopathologic examination (R1 resection according to UICC). No palliative resections leaving behind macroscopically gross tumor (R2 resections) were performed.
Perioperative mortality occurred in 3 patients (4.05%). All 3 perioperative deaths (4.05%) were related to septical complications resulting from surgical complications (anastomotic leakage, 2; or necrosis of the interpositioned gastric tube, n ϭ 1).
Survival Analysis
Median follow-up is 20.3 months (range, 5.9 -78.7 months) for the 41 patients surviving to the last follow-up. Overall survival was measured from the date of the operation to the date of death for resected patients and from the last day of neoadjuvant treatment until death for nonresected patients.
Kaplan-Meier survival curves are shown in Figure 1 for all patients and in Figure 2 for patients with complete (R0) and incomplete (R1) resections as well as patients who progressed under neoadjuvant therapy and did not proceed to surgical resection. All patients with tumor progression during radiochemotherapy or incomplete (R1) resections died during follow up (3-year survival rates, 0%). In contrast, patients with R0 resections had a significant survival advantage (logrank, P Ͻ 0.01) with estimated 3-year survival rates of 54% (Ϯ7.05% SE).
Univariate survival analysis of resected tumors demonstrated that the ypT categories (P ϭ 0.08) and grading of the primary tumor (P ϭ 0.33) did not significantly influence survival probabilities. In contrast, the presence of lymph node metastases was significantly associated with lower median (16.3 Ϯ 3.8 for ypN1 versus 43.5 Ϯ 10.9 months for ypN0) or 3-year survival probabilities (35.5 Ϯ 8.6 for ypN1 versus 68.6 Ϯ 9.2% for ypN0). Detailed results of univariate survival analyses are summarized in Table 2 .
Comparison of Squamous Cell Carcinomas and Adenocarcinomas
No significant differences in the resection rates, frequency of tumor progression, perioperative mortality, or ypT and ypN categories between the 2 histologic types were detected (Table 3) . Response classifications did not differ between squamous cell cancer and adenocarcinomas (P ϭ 0.7).
Survival analysis for resected cases did not show a significant difference in median and estimated 3-year survival probabilities between the 2 histologic entities ( Table 2) .
Downstaging of the Tumor and Lymph Node Categories
Objective downstaging from the cT2/T3 categories to ypT0 (pCR) occurred in 11 of 74 (14.9%) resected cases. In cases with less than 10% VRTCs (grade III regression), objective downstaging from cT2 to ypT1, or cT3 to ypT1-2, was observed in only 1 of 19 (5.3%) patients. Despite massive reduction of vital tumor cells greater than 90%, the original T category was maintained. This demonstrated that objective downstaging of the cT category, aside from pathologic complete remission (ypT0), is a rare exception. In Figure 3 , the frequencies of nodal metastases for response grades I to IV are shown. There was a significant association FIGURE 1. Overall survival of all 85 patients. Median survival was 23 months and the 3-year survival rate was 31% Ϯ 7%.
FIGURE 2. Kaplan-Meier survival curves for patients with complete resections (RO), incomplete resections with microscopic involvement of a resection margin (R1), and patients without resection due to tumor progression during neoadjuvant radiochemotherapy (PR).
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Histomorphologic Regression in Esophageal Cancer between regression grades and ypN categories (P Ͻ 0.003), pointing out that regression was not restricted to the primary tumor.
Classification of Histomorphologic Tumor Regression
Frequencies of histomorphologic tumor regression grades I to IV are shown in Table 3 for squamous cell carcinomas and adenocarcinomas. Univariate survival analysis demonstrates a significant association of regression grades and survival (P Ͻ 0.03); data are shown in Table 2 .
There was, however, no significant difference in median survival probabilities between grades I and II or grades III and IV, respectively. Therefore, grades I and II were combined within the group of minor histomorphologic response and grades III and IV within the group of major histomorphologic response. Univariate survival analysis by log-rank testing revealed an improved statistically significant difference (P Ͻ 0.004) by dividing histomorphologic response classification into 2 groups. The respective median and 3-year survival probabilities are shown in Table 2 and Kaplan-Meier curves in Figure 4 . A Cox regression model 29 was used to simultaneously test the 3 variables in the completely resected (R0) cases that were significant (ypN categories, dichotomized regression grades) or tended to influence the survival probabilities (ypT categories) by univariate survival analysis (log-rank testing).
The overall model was significant with a P Ͻ 0.005, and the final model after elimination of ypT categories (P ϭ 0.9) had a P value of Ͻ0.002. In the final model, the dichotomized regression grades (minor and major histomorphologic regression, P Ͻ 0.028) and ypN categories (ypN0 and ypN1, P Ͻ 0.036) were significant prognostic indicators, whereas downstaging of the primary tumor, reflected in the ypT categories (P ϭ 0.9), did not influence survival.
Response Classification System
Based on the results of the multivariate analysis, a response classification system was tested which included the following 4 categories:
1. Minor histomorphologic regression (grades I/II) with lymph node metastases (ypN1) 2. Minor histomorphologic regression (grades I/II) without lymph node metastases (ypN0) 3. Major histomorphologic regression (grades III/IV) with lymph node metastases (ypN1) 4. Major histomorphologic regression (grades III/IV) without lymph node metastases (ypN0)
Univariate survival analysis of this response classification system showed a significant difference (P Ͻ 0.001) in median survival estimates. The respective Kaplan-Meier curves are shown in Figure 5 . ; grade I, Ͼ50% vital residual tumor cells (VRTCs); grade II, 10%-50% VRTCs (partial response); grade III, nearly complete response (NCR) with Ͻ10% VRTCs; grade IV, complete response (pCR, ypT0); MiHR, minor histomorphologic regression; MaHR, major histomorphologic regression; ypT/ypN, histopathologic tumor/lymph node categories following neoadjuvant treatment according to UICC. 24 
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DISCUSSION
Neoadjuvant treatment strategies for esophageal cancer are a matter of ongoing debate with controversial results from phase II and III trials. However, there is a consensus that patients with pathologic complete remissions after neoadjuvant chemotherapy or chemoradiation trials definitively ben- 5. Kaplan-Meier curves for patients with minor histomorphologic regression with (class Ia; n ϭ 29) and without (class Ib; n ϭ 14) lymph node metastases compared with major histomorphologic regression with (class IIa; n ϭ 9) and without (class IIb; n ϭ 22) lymph node metastases.
Annals of Surgery • Volume 242, Number 5, November 2005
Histomorphologic Regression in Esophageal Cancer efit from these treatment modalities with 5-year survival rates up to 60%. 2, 13, 14 Clinical response evaluation based on WHO criteria 15 is known to be highly inaccurate in esophageal cancer using conventional staging modalities, including barium swallow, endoscopy, endosonography, or CT of chest and abdomen. 16, 30, 31 Positron emission tomography (PET) with 18-fluorodeoxyglucose might offer improved specificity and accuracy for clinical response evaluation 32, 33 or response prediction. 34 It has been shown, however, that PET imaging clearly improves staging of esophageal cancers primarily through increased sensitivity and specificity in the detection of distant metastases. [35] [36] [37] Frequencies of pathologic complete remissions show considerable variation from 0% to 12.8% for neoadjuvant chemotherapy 8, 38 and 10% to 39% for induction radiochemotherapy 2, 38 in patients with esophageal cancer. A comparative analysis of histopathologic effects of chemo-, radio-, or radiochemotherapy on locally advanced esophageal cancers displayed markedly increased histomorphologic regression signs in the radiochemotherapy group. 39 This is a reflection of the higher response rates observed in clinical radiochemotherapy protocols. 40 Variation in frequencies of complete remissions in combined modality protocols might further depend on the combination, dosage, and mode of administration of systemic agents and radiation therapy. An optimal protocol has yet to be defined. 2, 41, 42 Studies using clinical response classifications according to WHO criteria 15 did not further differentiate the group of partial response (Ͼ50% tumor regression) and might underestimate the number of patients with an impressive survival benefit despite the presence of minimal residual tumor. Mandard et al 20 reported a similar quantitative regression model in patients with esophageal squamous cell cancer receiving neoadjuvant radiochemotherapy (cisplatin, 37 Gy). These authors used 5 tumor regression classes (TRG 1-5) including a group with pathologic complete remission (TRG 1) and microscopic foci of residual tumor (TRG 2), the latter being practically identical to our regression grade III with estimated Ͻ10% VRTCs. Consistent with our results, TRG 1-2 showed a statistically significant survival benefit (P Ͻ 0.001) compared with other regression classes. This has also been reported for patients with stage IIIA/B non-small cell lung cancer 21, 43 or rectal cancer 44, 45 treated with neoadjuvant radiochemotherapy, as well as locally advanced gastric cancer treated with neoadjuvant chemotherapy. 18 In agreement with our results, no statistically significant difference could be detected between pathologic complete remission and microscopic residual disease in patients with esophageal cancer, 20 regression with estimated Ͻ10% VRTCs in patients with non-small cell lung cancer or gastric cancer, 18, 21, 43 or Ͻ 5% VRTCs in rectal cancer patients. 44, 45 Small foci of vital residual tumor cells might be easily missed during histopathologic examination, especially when en bloc tumor embedding is not performed and only few sections are evaluated. 18, 20, 46 This lack of standardized pathologic workup might significantly contribute to variation in frequencies of pathologic complete remissions between protocols. This could result in an underestimation of microscopic residual disease and an overestimation of complete response. Based on our results and the observations in other solid tumors including stomach, rectal, and non-small cell lung cancer, 18, 21, [43] [44] [45] a simple response classification system that separates major histomorphologic regression (minimal residual disease or Ͻ10% VRTCs) from minor histomorphologic regression appears to be justified.
The superiority of histomorphologic regression analysis to downstaging of the T category is best shown in the group of 19 tumors with Ͻ10% VRTCs (grade 3 regression) in our study. Anatomic location of microscopic residual foci with regard to the layers of the esophageal wall revealed true downstaging in only 1 of 19 tumors (cT2 to ypT1). In 18 of 19 tumors, the original T category was preserved, which clearly demonstrates that histomorphologic regression grading is more accurate than histopathologic downstaging to objectively identify major response. Moreover, it identifies the "problem zone" in the periadventitious area of T3/T4 tumors and mandates that locally advanced esophageal cancers should be included in neoadjuvant protocols only if they are deemed to be resectable prior to neoadjuvant treatment.
Histopathologic effects of neoadjuvant chemo-or radiochemotherapy were also observed in lymph node metastases. 18, 47 The presence of lymph node metastases is a strong indicator for poor outcome in esophageal cancer. Frequencies of ypN0 categories have been reported to be higher in patients receiving neoadjuvant radiochemotherapy. 10, 48 We demonstrated a statistically significant increase of ypN0 categories (P Ͻ 0.003) in association with major histopathologic regression (Fig. 3) . Clearly, this indicates response to neoadjuvant treatment. This association was also reported in patients with rectal cancer. 49 Logistic regression analysis in patients with R0 resections identified ypN category (P Ͻ 0.036) as a prognostic indicator second only to the grade of histomorphologic regression of the primary tumor (P Ͻ 0.028). This implicates that an objective regression classification system should include the 2 variables as suggested (Table 4) .
CONCLUSION
The advantages of such an objective and clinically relevant regression classification system are obvious. Among them is the possibility to precisely compare the efficacy of various treatment protocols. Diagnostic procedures can be more objectively evaluated for their accuracy to predict or 
